EBiSC2

EBiSC2 – A sustainable European bank for induced pluripotent stem cells
EBISC2 logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 13
Grant agreement number
821362

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
4 599 648
EFPIA in kind
4 272 964
Total Cost
8 872 548

Summary

Induced pluripotent stem cells (iPSCs) are key tools for early drug development and disease modelling. IPSCs are mature adult cells that have been reprogrammed to make them ‘pluripotent’, i.e. able to differentiate into any type of cell found in the human body.

EBiSC2 aims to become a self-sustaining biobank, providing well-characterised, quality controlled iPSCs to the academic and industrial scientific communities worldwide. Building on the work of previous projects, including IMI’s EBiSC, EBiSC2 will provide access to a broad catalogue of iPSCs from diverse disease and genetic backgrounds along with comprehensive datasets. They will also offer the bulk production of iPSCs and the delivery of pre-differentiated cell populations. By supporting future iPSC-based disease research, EBiSC2 will contribute to the discovery and development of new drugs.

Achievements & News

Working on iPSCs? EBiSC2 wants your opinion
September 2019

IMI’s EBiSC project has established a centralised, not-for-profit human induced pluripotent stem cell (iPSC) bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality iPSCs for use in research and medicines development.### Since its creation in 2014, the bank has grown considerably and now provides a large range of iPSC lines and services to academics, non-profit organisations and companies. Projects generating iPSCs can also make their cell lines sustainable by depositing them in the EBiSC catalogue, ensuring secure long-term storage and simplified access and distribution.

The new EBiSC2 project builds on the achievements of the original EBiSC project, including improving its services and providing new iPSC lines and differentiated cell products. To ensure the project continues to offer products and services that are relevant to the scientific community, EBiSC is running a survey. The survey is open until the end of October.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Fujifilm Cellular Dynamics Inc, Madison, United States
  • H. Lundbeck As, Valby, Denmark
  • Institut De Recherches Servier, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Takeda Development Centre Europe LTD., London, United Kingdom
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Bioneer A/S, Horsholm, Denmark
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Department of Health, Leeds, United Kingdom
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Katholieke Universiteit Leuven, Leuven, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Arttic, Paris, France
Third parties
  • Fraunhofer Uk Research Limited, Glasgow, United Kingdom

CONTACT

Project coordinator
Heiko ZIMMERMANN
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
heiko.zimmermann[at]ibmt.fraunhofer.de